Need a research contact?
Looking for studies by practice area?

RESEARCH TEAM CONTACT LISTS
(click practice area to find team list):

• Valve / Structural Heart Team
• Interventional / Endovascular / Imaging / CCAD Team
• HF / Regenerative Therapies Team
• EP / Prevention Team

STUDY LISTS
(click practice area to find study list):

• Valve / Structural Heart Studies
• Interventional / Endovascular / Imaging / CCAD Studies
• HF / Regenerative Therapies Studies
• EP / Prevention Studies

Bookmark this web link to access a list of current, open featured studies: mplsheart.org/studies
MHIF Practice Areas
*(click links below to access study and team contact lists)*

- Valve / Structural Heart
- Interventional / Endovascular / Imaging / CCAD Science Center
- HF / Regenerative Therapies
- EP / Prevention

Bookmark this web link to access a list of current, open featured studies: mplsheart.org/studies
MHIF Featured Studies
Valve/Structural Heart

MHIF RESEARCH CONTACTS FOR: Valve / Structural Heart

- **Accurate IDE** for Symptomatic Severe Aortic Stenosis (AS)
- **Altflo** for Symptomatic clinically significant heart failure and elevated atrial pressures
- **Early TAVR** for asymptomatic, severe, calcific Aortic Stenosis (AS)
- **Evolut Low-Risk** for severe aortic valve stenosis in low surgical risk patients
- **TRILUMINATE Pivotal** for severe tricuspid regurgitation

Bookmark this web link to access a list of current, open featured studies: [mplsheart.org/studies](http://mplsheart.org/studies)
MHIF Featured Studies:
Interventional/Endovascular/Imaging/CCAD Science Center

MHIF RESEARCH CONTACTS FOR: Interventional / Endovascular / Imaging / CCAD

- Disrupt CAD III for calcified coronary artery disease
- ECLIPSE for Coronary Artery Disease
- MINT for Myocardial Ischemia and Transfusion
- Radiance II for hypertension
- Radiance HTN for hypertension
- Spyral HTN for hypertension

Bookmark this web link to access a list of current, open featured studies: mplsheart.org/studies
MHIF Featured Studies:
HF/Regenerative Therapies

MHIF RESEARCH CONTACTS FOR: HF / Regenerative Therapies

- CORCINCH-HFrEF – ACCUCINCH 5017 ventricular repair system in patient with reduced EF
- Guide HF for heart failure
- Heart EXPAND CAP for heart failure/transplant
- Heart FID Heart failure with iron deficiency anemia
- HITSOVA for Heparin-Induced Thrombocytopenia
- Reduce LAP-HF RCT II for heart failure

Bookmark this web link to access a list of current, open featured studies: mplsheart.org/studies
MHIF Featured Studies: EP/Prevention

MHIF RESEARCH CONTACTS FOR: EP / Prevention

- AEGIS 2 for acute coronary syndrome
- AKI for Preventing AKI post OHS
- Artesia for sub-clinical atrial fibrillation (SCAF) detected by PPM, ICD, or ICM
- Cascade FH Registry for familial hypercholesterolemia
- Prominent for high triglycerides, low HDL, T2DM, secondary cardiovascular prevention
- QDOT for paroxysmal atrial fibrillation
- Rhapsody for pericarditis
- Vesalius for high cardiovascular risk without prior myocardial infarction or stroke
- VISITAG SURPOINT for atrial fibrillation
- WARRIOR for non-obstructive CAD in Women

Bookmark this web link to access a list of current, open featured studies: mplsheart.org/studies
VALVE AND STRUCTURAL STUDIES
MHIF FEATURED STUDY: ACURATE IDE

DESCRIPTION:
To evaluate safety and effectiveness of the ACURATE neo 2™ Transfemoral Aortic Valve System for transcatheter aortic valve replacement (TAVR) in symptomatic subjects with severe aortic stenosis who are considered at intermediate or greater risk for surgical valve replacement. Prospective, multicenter, 1:1 randomization to any commercially available TAVR device.

CRITERIA LIST/QUALIFICATIONS:

Inclusion
1. Severe native aortic stenosis defined as initial AVA ≤1.0 cm² (or AVA index ≤0.6 cm²/m²) AND a mean pressure gradient ≥40 mm Hg OR maximal aortic valve velocity ≥4.0 m/s OR Doppler velocity index ≤0.25 as measured by echocardiography and/or invasive hemodynamics
2. Aortic annulus size of ≥21 mm and ≤27 mm
3. Symptomatic aortic valve stenosis per IC1 definition above with NYHA Functional Class ≥ II

Exclusion
1. Unicuspid or bicuspid aortic valve.
2. Previous acute myocardial infarction within 30 days prior to the index procedure
3. Subject has severe aortic, tricuspid, or mitral regurgitation
MHIF FEATURED STUDY: ALTFLO

OPEN AND ENROLLING: EPIC message to “Research MHIF Patient Referral”

DESCRIPTION:
Multi-center, prospective, early feasibility study to evaluate initial clinical safety, device functionality and effectiveness of the Edwards Transcatheter Atrial Shunt System.

CRITERIA LIST/QUALIFICATIONS:

**Inclusion**
1. Chronic symptomatic Heart Failure (HF)
2. Stable Guideline Directed Medical Therapy (GDMT) for heart failure management
3. Elevated LA (or PCWP) pressure of >15 mmHg at rest or >25 mmHg during supine ergometer exercise stress test.

**Exclusion**
1. Severe HF
   1. ACC/AHA/ESC Stage D, non ambulatory NYHA IV
   2. Cardiac index <2.0L/min/m2
   3. Inotropic infusion
   4. Listed for cardiac transplant
   5. LVEF <20%
2. Presence of significant valve disease (>3+MR, >2+TR, >2+ AR or > moderate AS)

CONDITION:
Symptomatic clinically significant heart failure and elevated atrial pressures

PI:
Paul Sorajja, MD

RESEARCH CONTACT:
Karen Meyer, RN
Karen.meyer2@allina.com | 612-863-5855

SPONSOR:
Edwards LifeScience

CONDITION:
Symptomatic clinically significant heart failure and elevated atrial pressures

PI:
Paul Sorajja, MD

RESEARCH CONTACT:
Karen Meyer, RN
Karen.meyer2@allina.com | 612-863-5855

SPONSOR:
Edwards LifeScience
MHIF FEATURED STUDY:
Early TAVR Trial

DESCRIPTION:
Prospective, multicenter study, randomized 1:1 with the SAPIEN 3 valve or clinical surveillance. Patients must have suitable anatomy for transfemoral Transcatheter Aortic Valve Replacement (TAVR). 75 sites in the U.S. and 1109 patients will be enrolled.

PARTIAL CRITERIA LIST/QUALIFICATIONS:

Inclusion
- Aortic valve area (AVA) ≤ 1.0 \( \text{cm}^2 \) or AVA index ≤ 0.6 \( \text{cm}^2/\text{m}^2 \)
- Peak jet velocity ≥ 4.0 m/s or Mean gradient ≥ 40 mmHg
- Negative treadmill stress test
- EF ≥ 50%

Exclusion
- NYHA ≥ 2, hx of syncope, HF hospitalization within last 12 mo
- Concomitant valvular or CAD requiring surgery
- Acute MI ≤ 30 days before randomization

RESEARCH CONTACT:
Aisha Ahmed
Aisha.Ahmed@allina.com | 612-863-9362

SPONSOR:
Edwards Lifesciences

ACTION: Do you see patients with severe aortic stenosis but remain asymptomatic?
If so, please contact Dr. Garcia or Aisha Ahmed (Study Coordinator)
aisha.ahmed@allina.com
**MHIF FEATURED STUDY:**

**EVOLUT Low-Risk**

**DESCRIPTION:**
Transcatheter aortic valve replacement (TAVR) with FDA approved Medtronic Evolut TAVR system for patients at low surgical risk for surgical aortic valve replacement (SAVR). Subjects are randomized 1:1 to either TAVR or SAVR. This study is comparing SAVR to TAVR in a new patient population for this approved device.

**CRITERIA LIST/ QUALIFICATIONS:**

**Inclusion**
- Severe aortic stenosis, either symptomatic or asymptomatic (no bicuspid valves)
- Documented heart team agreement that the subject is considered low surgical risk (predicted risk of mortality for SAVR < 3% at 30 days)
- Follow-up is for 10 years

**CONDITION:**
Severe aortic valve stenosis in low surgical risk patients

**PI:**
Paul Sorajja, MD

**RESEARCH CONTACT:**
Karen Meyer, RN
Karen.meyer2@allina.com | 612-863-5855

**SPONSOR:**
Medtronic

**Status:**
In Follow-Up
**MHIF FEATURED STUDY:**
**TRILUMINATE Pivotal**

**DESCRIPTION:**
Prospective, randomized, multicenter trial of TriClip™ device in symptomatic patients with severe tricuspid regurgitation (TR) who have been determined to be at intermediate or greater estimated risk for mortality with tricuspid valve surgery.

**PARTIAL CRITERIA LIST/ QUALIFICATIONS:**

**Inclusion**
- Symptomatic severe TR despite optimal medical therapies (drug and/or device)
- Adequately treated per applicable standards and stable for 30 days
- Intermediate or greater surgical risk of mortality with tricuspid valve surgery

**Exclusion**
- Systolic pulmonary artery pressure (sPAP) >70 mmHg
- Severe uncontrolled hypertension Systolic Blood Pressure (SBP) ≥180 mmHg and/or Diastolic Blood Pressure (DBP) ≥110mmHg
- Pacemaker or ICD leads that would prevent appropriate placement of TriClip
- Left Ventricular Ejection Fraction (LVEF) ≤ 20%

<table>
<thead>
<tr>
<th>CONDITION:</th>
<th>NATIONAL PI:</th>
<th>RESEARCH CONTACT:</th>
<th>SPONSOR:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe Tricuspid Regurgitation (TR)</td>
<td>Paul Sorajja, MD</td>
<td>Kate Jappe, RN</td>
<td>Abbott Vascular Inc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td><a href="mailto:Kate.Jappe@allina.com">Kate.Jappe@allina.com</a></td>
<td>612-863-7347</td>
</tr>
</tbody>
</table>

**NATIONAL PI:** Paul Sorajja, MD

**RESEARCH CONTACT:** Kate Jappe, RN
Kate.Jappe@allina.com | 612-863-7347

**SPONSOR:** Abbott Vascular Inc.
STUDIES FOR:
Interventional
Endovascular
Imaging
CCAD Science Center
**MHIF FEATURED STUDY:**

**DISRUPT CAD III**

**DESCRIPTION:**
Phase III study to assess the safety and effectiveness of the Shockwave Coronary Intravascular Lithotripsy (IVL) System to treat de novo, calcified, stenotic, coronary lesions prior to stenting.

**PARTIAL CRITERIA LIST/QUALIFICATIONS:**

**Inclusion**
- Untreated severely calcified lesion in a coronary artery
- Vessel size 2.5mm to 4.0mm
- 70-99% stenosis

**Exclusion**
- STEMI
- Previous stented target lesion

**CONDITION:**
Calcified Coronary Artery Disease

**PI:**
Nicholas Burke, MD

**RESEARCH CONTACT:**
Jo Anne Goldman, RT
JoAnne.Goldman@allina.com | 612-863-3793

**SPONSOR:**
Shockwave Medical

**OPEN AND ENROLLING:**
EPIC message to “Research MHIF Patient Referral”

**ACTION:**
Are the patients you are referring for coronary angiography appropriate for this trial?

Contact Dr. Burke or Jo Anne Goldman, RT (Study Coordinator) joanne.goldman@allina.com
MHIF FEATURED STUDY: ECLIPSE

DESCRIPTION:
Prospective, randomized 1:1 (stratified by site single lesion vs multiple lesion) multicenter trial to evaluate Orbital Atherectomy compared to conventional balloon angioplasty technique for the treatment of severely calcified lesions prior to implantation of drug-eluding stents.

PARTIAL CRITERIA LIST/QUALIFICATIONS:
Inclusion
Present with stable ischemic heart disease, NSTEMI or USA, or stabilized recent STEMI > 48hr with severe calcification
Excludes patients with previous PCI within 12 months
Excludes patients unable to take DAPT for min. of 6 months

CONDITION: Coronary Artery Disease
PI: Ivan Chavez, MD
RESEARCH CONTACT: Amy McMeans
amy.mcmeans@allina.com | 612-863-3895
SPONSOR: Cardiovascular Systems, Inc.

OPEN AND ENROLLING: EPIC message to “Research MHIF Patient Referral”
MHIF FEATURED STUDY: MINT

**CONDITION:** Myocardial Ischemia and Transfusion

**PI:** Jay Traverse, MD

**RESEARCH CONTACT:** Rose Peterson
Rose.Peterson@allina.com | 612-863-6051

**SPONSOR:** NIH Trial

**STATUS:** In Follow-Up

Evidence suggests it is safe to wait to give a blood transfusion; however, for those who have suffered a heart attack, there is a lack of high-quality evidence to guide transfusions. The study’s results will influence transfusion practice worldwide.

**DESCRIPTION:**

MINT is a multicenter randomized clinical trial comparing red blood cell transfusion strategies for patients who have had a myocardial infarction and are anemic (positive troponins and a hemoglobin of less than 10 g/dL).

The trial will enroll 3500 hospitalized patients diagnosed with myocardial infarction who are anemic (have blood counts less than 10 g/dL) to receive either a liberal or a restrictive transfusion strategy. Patients will be followed for 6 months to assess how well they are recovering from their heart attack.

**CRITERIA LIST/QUALIFICATIONS:**

Inclusion
Positive Troponin and a hemoglobin of less than 10 g/dL
MHIF FEATURED STUDY:
RADIANCE II Study

DESCRIPTION:
Designed to assess potential therapeutic benefits of catheter directed renal denervation in managing essential and resistant hypertension. The study objective is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at time of consent. Prior to randomization, subjects will be hypertensive in the absence of hypertension medication.

CRITERIA LIST/QUALIFICATIONS:

Inclusion
- Age 18-75 years at time of consent (reduces potential that hypertension is due entirely to stiff arteries)
- History of being “treated” with antihypertensive medications
- Uncontrolled at screening visit (average seated office BP ≥ 140/90 mmHg and < 180/120 mmHg) on no more than 2 antihypertensive medications
- Must remain uncontrolled (daytime ABP ≥ 135/85 mmHg and < 170/105 mmHg) after a 4-week washout/run-in period
- Must have an eligible renal anatomy documented by MRA or CTA and confirmed by renal angiogram at procedure (where applicable)

Exclusion
- Lacks appropriate renal artery anatomy for treatment; known, uncorrected causes of secondary hypertension other than sleep apnea
- Type I diabetes mellitus or uncontrolled Type II diabetes; eGFR of <40; Brachial circumference ≥ 42 cm
- History of cerebrovascular event or severe cardiovascular event, or history of stable or unstable angina within 12 months; Repeat (>1) hospitalization for hypertensive crisis

CONDITION: Hypertension
PI: Yale Wang, MD
RESEARCH CONTACT: Rose Peterson
Rose.Peterson@allina.com | 612-863-6051
SPONSOR: ReCor

OPEN AND ENROLLING:
EPIC message to “Research MHIF Patient Referral”

HOPE
DISCOVERED HERE
Creating a world without heart and vascular disease
RADIANCE-HTN

- CONDITION: Hypertension; Vascular Diseases
- CONTACT INFO: Rose Peterson, RN | Rose.Peterson@allina.com | 612-863-6051
- DESCRIPTION: Hypertension, or high blood pressure, affects over 1 billion people. Left untreated, high blood pressure can increase your risk of serious health problems such as heart attack, stroke, and kidney failure. Yet nearly 1 in 3 individuals with hypertension struggle to control their blood pressure despite being on medication.

If you and your physician have been unable to control your blood pressure, or are interested in an alternative to daily medications, you may be a candidate for the RADIANCE-HTN Clinical Study. The study is evaluating an investigative minimally-invasive, catheter-based procedure (the Paradise® Renal Denervation System) which may lower your blood pressure and reduce your need for blood pressure medications.

- CRITERIA LIST/QUALIFICATIONS: Complete this questionnaire to see if you qualify to participate in the Radiance-HTN Study.
- INVESTIGATORS: Yale Wang, MD
- SPONSORS: ReCor Medical
- STATUS: Open/Enrolling
**MHIF FEATURED STUDY:**
**SPYRAL-HTN**

**DESCRIPTION:**
The aim of the study is to test the hypothesis that renal denervation is safe and reduces systolic blood pressure (SBP) in patients with uncontrolled hypertension compared to a sham controlled population, in the absence of antihypertensive medications (OFF MED) or uncontrolled hypertension on one, two, or three standard antihypertensive medications (ON-MED).

**PARTIAL CRITERIA LIST/QUALIFICATIONS:**

**Inclusion**
- Office systolic blood pressure (SBP) ≥150mmHg and <180mmHg and an office diastolic blood pressure (DBP) ≥90mm Hg with or without meds

**Exclusion:**
- Main renal artery < 3 mm or > 8 mm ; eGFR <45 ml/min
- *Screen failure if OSBP> or = 180 mm Hg*
HEART FAILURE/REGENERATIVE STUDIES
MHIF FEATURED STUDY: CORCINCH-HFrEF (aka ACCUCINCH 5017)

<table>
<thead>
<tr>
<th>ACCUCINCH ventricular repair system in patient with reduced EF</th>
<th>PI: Peter Eckman, MD</th>
<th>RESEARCH CONTACT: Jake Jensen <a href="mailto:Jacob.jensen@allina.com">Jacob.jensen@allina.com</a></th>
<th>SPONSOR: Ancora Heart</th>
</tr>
</thead>
</table>

**DESCRIPTION:**

The objective of this trial is to evaluate the safety and performance of the AccuCinch system in patients with HFrEF.

**CRITERIA LIST / QUALIFICATIONS:**

**Inclusion**
- Dilated Ischemic Cardiomyopathy or Non Ischemic Cardiomyopathy; NYHA III-Iva; LVEF ≥ 20 and ≤ 40%

**Exclusion**
- No mod-severe MR, AR, or AS; TAPSE >14, severe TR; no AV prosthesis; LVEDD must be ≥ 55 mm > 3m from CRT or > 1m from ICD implant or revision (LBBB and QRS >150 required to have CRT)

~6.5 million Americans and ~25 million people worldwide have HF. Projections show that the prevalence of HF will increase 46% from 2012 to 2030, resulting in >8 million people ≥18 years of age with heart failure.
MHIF Featured Study: **Guide HF**

**CONDITION:**
Heart Failure

**PI:** Mosi Bennett, MD
**CONTACT:** Sarah Schwager 612-863-6257
Kari Thomas, 612.863.7493

**SPONSOR:** Abbott Vascular

**DESCRIPTION:**
Study comparing CardioMEMS sensor to standard of care heart failure treatment. There are **1.2+ MILLION hospitalizations** for decompensation of heart failure annually.

The CardioMEMS sensor is a wireless PA pressure monitoring system which enables providers to proactively treat heart failure and reduce the likelihood of hospitalization.

**PARTIAL CRITERIA LIST / QUALIFICATIONS:**

**Inclusion**
- All heart failure patients (NYHA Class II-IV)
- Patients with and without a prior heart failure hospitalization

**Exclusion**
- Received or are likely to receive an LVAD or heart transplant

**REFER PATIENTS!**
**MHIF FEATURED STUDY:**
**Heart EXPAND CAP**

**DESCRIPTION:** a single-arm study evaluating the OCS™ Heart System and extended criteria donor hearts (those that are currently not transplanted or are seldom transplanted in the US)

**CRITERIA LIST/ QUALIFICATIONS:**

**Donor Heart Inclusion**

- Expected total cross-clamp time of ≥4 hours; OR expected total cross-clamp time of ≥2 hours PLUS one of the following risk factors:
  - Donor age 45-55 years, inclusive, with no coronary catheterization data
  - Donor age ≥55 years
  - Left ventricular septal or posterior wall thickness of >12 mm, but ≤16 mm
  - Reported down time of ≥20 min, with stable hemodynamics at time of final assessment
  - Left heart ejection fraction (EF) ≥40%, but ≤50% at time of acceptance of offer
  - Donor angiogram with luminal irregularities with no significant CAD (≤50%)
  - History of carbon monoxide poisoning with good cardiac function at time of donor assessment
  - Social history of alcoholism with good cardiac function at time of donor assessment
  - History of diabetes without significant CAD on angiogram (≤50%)

**CONDITION:** Heart Failure/Transplant

**PI:** Karl Mudy, MD

**RESEARCH CONTACTS:**
- Kari Thomas - Kari.M.Thomas@allina.com | 612-863-7493
- Kari Williams - Kari.Williams@allina.com | 612-863-0027

**SPONSOR:** TransMedics, Inc.

**OPEN AND ENROLLING:**
EPIC message to “Research MHIF Patient Referral”
Heart-FID

OPEN AND ENROLLING:
EPIC message to “Research MHIF Patient Referral”

• **CONDITION:** Heart failure with iron deficiency anemia
• **PI:** Peter Eckman, MD
• **CONTACT INFO:** Stephanie Ebnet, RN | stephanie.ebnet@allina.com | 612-863-6286
  Sarah Schwager, RN | sarah.schwager@allina.com | 612-863-6257

**DESCRIPTION:** This is a randomized, double blind, placebo-controlled study to investigate the efficacy and safety of Injectafer® (ferric carboxymaltose) as treatment for heart failure with iron deficiency. Study drug administration will occur as two intravenous doses every six months for duration of study.

**CRITERIA LIST/ QUALIFICATIONS:**

- **Inclusion:**
  - Ejection fraction ≤35%
  - Stable heart failure (NYHA II-IV) on maximally tolerated background therapy
  - Hemoglobin 9.0-13.5 g/dL (females) or <15.0 g/dL (males), serum ferritin <100 ng/mL or 100-300 ng/mL with TSAT <20%

- **Exclusion:**
  - Current or planned LVAD or heart transplantation, history of recent cardiovascular events, and significant co-morbidities

**SPONSOR:** Luitpold Pharmaceuticals, Inc.
**MHIF FEATURED STUDY:**
**HITSOVA**

**CONDITION:**
Heparin Induced Thrombocytopenia

**PI:**
Nedaa Skeik, MD

**RESEARCH CONTACTS:**
Carina Benson: carina.benson@allina.com
612-863-4393 | pgr: 612-654-5542
Jane Fox: jane.fox@allina.com | 612-863-6289

**SPONSOR:**
Aspen Global, Inc.

**DESCRIPTION:**
Open-Label, Randomized, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects with Acute HIT (HITSOVA study)

**CRITERIA LIST/QUALIFICATIONS:**

<table>
<thead>
<tr>
<th>Inclusion</th>
<th>Exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Males or females aged ≥2 weeks</td>
<td>Life expectancy less than study duration of 44 days</td>
</tr>
<tr>
<td>Subjects with suspected HIT by 4Ts of &gt;3 and with reduction of platelet count of ≥ 30% at either: a) Between Day 4 and 14 of the start of heparin exposure OR b) At Day 1 of heparin exposure with pre-treatment with heparin within the last 30 days</td>
<td>Lumbar puncture or spinal/epidural catheter placement within past 48 hrs</td>
</tr>
<tr>
<td>Have adequate renal function: Glomerular filtration rate ≥ 15 mL/min/1.73 m²</td>
<td>Severe hepatic impairment (Child-Pugh Class C)</td>
</tr>
<tr>
<td></td>
<td>Active bleeding</td>
</tr>
<tr>
<td></td>
<td>Hemorrhagic cerebrovascular accident within previous 3 mos.</td>
</tr>
<tr>
<td></td>
<td>Severe, uncontrolled hypertension defined as blood pressure &gt;180/110 mmHg</td>
</tr>
<tr>
<td></td>
<td>Diabetic retinopathy</td>
</tr>
</tbody>
</table>

**OPEN AND ENROLLING:**
EPIC message to “Research MHIF Patient Referral”
**MHIF FEATURED STUDY:**
**REDUCE LAP-HF RCT II**

**DESCRIPTION:**
A study to evaluate the Corvia Medical, Inc. IASD® System II to **REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure**

<table>
<thead>
<tr>
<th>CONDITION:</th>
<th>Heart Failure</th>
<th>PI:</th>
<th>Michael Samara, MD</th>
<th>RESEARCH CONTACT:</th>
<th>Jane Fox</th>
<th><a href="mailto:jane.fox@allina.com">jane.fox@allina.com</a></th>
<th>612-863-6289</th>
<th>SPONSOR:</th>
<th>Corvia Medical Inc.</th>
</tr>
</thead>
</table>

**CRITERIA LIST/QUALIFICATIONS:**

**Inclusion**
- Age > 40 years – GDMT for 4 weeks
- HF requiring current treatment w/ diuretics for ≥ 30 days AND NYHA class II if a prior history of > NYHA class II, to ambulatory NYHA class IV
- IV diuretics or need for intensification of oral diuresis for HF 12 months prior; OR an NT-pro BNP value > 150 pg./ml in normal sinus rhythm, > 450 pg./ml in AFIB, or a BNP value > 50 in NSR or, > 150 in AFIB within past 6 months
- EF ≥ 40% within the past 6 months, without EF < 30% in the past 5 years
- End-expiratory PCWP during supine ergometer exercise ≥ 25 mm Hg, and > RAP by ≥ 5 mm Hg.

**Exclusion**
- Inability to perform 6-minute walk test (distance < 50 m), OR 6-minute walk test > 600 m
- Resting RAP > 14 mmHg
- MI and/or percutaneous cardiac intervention within past 3 months; CABG in past 3 months, or current indication for coronary revascularization; AVR (surgical AVR or TAVR) within past 12 months
- Significant PH with PVR > 3.5 Woods units at rest or at peak exercise
EP/PREVENTION STUDIES
**MHIF FEATURED STUDY:**
**AEGIS 2**

<table>
<thead>
<tr>
<th>CONDITION:</th>
<th>Acute Coronary Syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>PI:</td>
<td>Thomas Knickelbine, MD</td>
</tr>
<tr>
<td>RESEARCH CONTACT:</td>
<td>Stephanie Ebnet</td>
</tr>
<tr>
<td>SPONSOR:</td>
<td>CSL Behring</td>
</tr>
</tbody>
</table>

**DESCRIPTION:**
CSL112 is being developed for use in patients with ACS (diagnosed with either STEMI or NSTEMI and exclusive of unstable angina) to reduce the risk of CV death, MI, and stroke upon delivery of CSL112.

Evidence from the Apo-I Event Reducing in Ischemic Syndromes-I (AEGIS-I) study has demonstrated that administration of apoA-I increases cholesterol efflux in MI patients.

**CRITERIA LIST/QUALIFICATIONS:**

- **Inclusion**
  - Positive Troponin with at least 50% stenosis on > 1 epicardial artery or prior cath with at least 50% stenosis on > 1 epicardial artery or prior CABG
  - Additional risk factor: DM, > 65 y.o., prior hx of MI or PAD

- **Exclusion**
  - EF < 30%
  - ALT > 3 x ULN
  - GFR< 30
  - Body weight < 50 kg
  - Allergy to soy beans or peanuts
  - Plan for CABG

**PI:**
Thomas Knickelbine, MD

**RESEARCH CONTACT:**
Stephanie Ebnet
Stephanie.ebnet@allina.com | 612-863-6286

**SPONSOR:**
CSL Behring

**OPEN AND ENROLLING:**
Please Refer Patients to Steph!
**MHIF FEATURED STUDY:**

**AKI**

**DESCRIPTION:** To evaluate the efficacy of post-surgery treatment with ASP1128 (investigational medication) in subjects at risk for acute kidney injury (AKI) following coronary artery bypass graft (CABG) and/or valve surgery. ASP1128 is a potent and highly selective PPARδ modulator, that is believed to have protective effects on kidney cells that are under cellular stress as a result of ischemia, inflammation and oxidative stress following coronary artery bypass graft and/or valve (CABG/V) surgery. In addition, ASP1128 will reduce inflammatory responses and increased oxidative stress systemically which is expected to reduce the immediate consequences of stress responses following CABG/V surgery.

**CRITERIA LIST/ QUALIFICATIONS:**

**Inclusion**
- Subject undergoing non-emergent open chest cardiovascular surgery with use of CPB (i.e., CABG and/or valve surgery [including aortic root and ascending aorta surgery, without circulatory arrest])
- Subject has moderate/high risk of developing AKI following surgery (must have 2 risk factors):
  - Risk factors: age > 70, eGFR < 60, CHF, DM, proteinuria/albimunuria

**Exclusion**
- On another investigational medication
- GFR < 30
- Prior kidney transplant
- Known or suspected glomerulonephritis
- Endocarditis or active infection
- Surgery off pump
- IV Drug abuse
- Chronic liver disorder
- LVAD

**CONDITION:** Preventing AKI post OHS

**PI:** Dr. Shukrallah

**RESEARCH CONTACT:** Steph Ebnet
Stephanie.ebnet@allina.com | 612-863-6286

**SPONSOR:** Astellas Pharma Inc. (API)

Coming soon: Please Refer Patients!
ARTESIA

CONDITION: Sub-clinical atrial fibrillation (SCAF) detected by PPM, ICD, or ICM.

PI: JoEllyn Moore, MD

CONTACT INFO: Jacob Cohen, MS | jacob.cohen@allina.com | 612-863-4022

DESCRIPTION: Prospective, randomized, parallel group, double-blind trial to determine if the use of apixaban in patients with SCAF will reduce the incidence of stroke and systemic embolism compared to aspirin. The experimental part of being in this study is being randomized to either aspirin or apixaban.

CRITERIA LIST/QUALIFICATIONS:

Inclusion:
- Permanent pacemaker or defibrillator (with or without resynchronization) or insertable cardiac monitor capable of detecting SCAF
- At least one episode of device-detected SCAF ≥ 6 minutes in duration but no single episode > 24 hours in duration at any time prior to enrollment. Any atrial high rate episode with average > 175 beats/min will be considered as SCAF. No distinction will be made between atrial fibrillation and atrial flutter.
- Age ≥ 55 years
- Risk Factor(s) for Stroke:
  - Previous stroke, TIA or systemic arterial embolism OR Age at least 75 OR Age 65-74 with at least 2 other risk factors OR Age 55-64 with at least 3 other risk factors

Exclusion:
- Clinical atrial fibrillation documented by surface ECG (12 lead ECG, Telemetry, Holter) lasting ≥ 6 minutes, with or without clinical symptoms

SPONSOR: Hamilton Health Sciences Corporation through the Population Health Research Institute (PHRI)
Cascade FH Registry

**CONDITION:** Familial Hypercholesterolemia (FH), a genetic condition marked by dramatically high levels of LDL-C that are not related to diet or lifestyle.

**PI:** Thomas Knickelbine, MD

**CONTACT INFO:** Christine Majeski, RN | christine.majeski@allina.com | 612-863-3546

**DESCRIPTION:** A national registry tracking the longitudinal treatment, clinical outcomes and patient reported outcomes of FH with the aim of increasing awareness and family screening of FH.

**CRITERIA LIST/ QUALIFICATIONS:**

**Inclusion:**
- Patient with existing diagnosis of FH using one of the three diagnostic tools:
  - US MedPed Program Criteria
  - Simon Broome Register Criteria with a diagnosis of “probable”
  - Dutch Lipid Clinic Network Diagnostic Criteria with a diagnosis of “probable”
- Patients with FH genetic mutation

**Exclusion:**
- Patients with a known medical condition other than FH thought to contribute to hyperlipidemia (i.e. untreated hyperthyroidism, nephrotic syndrome, cholestasis hypopituitarism)

**SPONSOR:** FH Foundation
MHIF FEATURED STUDY: PROMINENT

CONDITION: High triglycerides, low HDL, T2DM, secondary cardiovascular prevention

PI: Dr. Matthew Chu
SUB I'S: Marc Newell, MD
        Thomas Knickelbine, MD
        Amy Cooley, CNP

DESCRIPTION: Placebo controlled trial of a potent fibrate, pemafibrate, to prevent MI, ischemic stroke, unstable angina requiring revascularization, and CV death in adults with T2DM.

CRITERIA LIST/QUALIFICATIONS:

Inclusion
TG > 200, HDL < 40, T2DM, LDL<70 or high dose statin or statin intolerant

Exclusion
Type 1 diabetes, HbA1c > 9.5%, NYHA Class IV HF, significant liver disease

RESEARCH CONTACT:
Ezi Ebere
Ezi.Ebere@allina.com | 612-863-4393

SPONSOR:
Kowa Research Institute

TRIGLYCERIDES MATTER – AND THIS STUDY IS HELPING ADDRESS THEM!

OPEN AND ENROLLING: EPIC message to “Research MHIF Patient Referral”

EPIC message to “Research MHIF Patient Referral”
MHIF FEATURED STUDY: QDOT

DESCRIPTION:
Prospective, non-randomized, pre-market clinical evaluation of the QDOT MICRO™ catheter for pulmonary vein isolation (PVI) in the treatment of subjects with paroxysmal atrial fibrillation.

PARTIAL CRITERIA LIST/QUALIFICATIONS:
Inclusion
Symptomatic paroxysmal AF with one electrocardiographically documented AF episode within 6 months prior to enrollment and a physician’s note indicating recurrent self-terminating AF within 7 days

Failed at least one (1) antiarrhythmic drug (AAD) (class I or III) as evidenced by recurrent symptomatic AF, contraindicated or intolerable to the AAD

Exclusion
Previous surgical or catheter ablation for atrial fibrillation
Patient on amiodarone at any time during ] past 3 months prior to enrollment
Previously diagnosed with persistent or long-standing persistent AF and/or continuous AF lasting > 7 days

CONDITION: Proxysmal Atrial Fibrillation (PAF)
PI: Daniel Melby, MD
RESEARCH CONTACT: Jacob Cohen
Jacob.Cohen@allina.com | 612-863-4022
SPONSOR: Biosense Webster

OPEN AND ENROLLING: Please Refer Patients!

ACTION: Are the patients you are referring for EP consultation and ablation appropriate for this trial? If so, please contact Dr. Melby or Jacob Cohen, MS (Study Coordinator) jacob.cohen@allina.com
# MHIF Featured Study: Rhapsody

**Description:**
First multinational, phase 3, double-blinded, placebo-controlled, randomized withdrawal, study assessing the efficacy of rilonacept, an interleukin 1 alpha and beta receptor decoy, in the treatment of recurrent pericarditis.

**Criteria List/Qualifications:**

**Inclusion**
- Diagnosis of recurrent pericarditis

**Exclusion**
- Pericarditis secondary to specific prohibited etiologies, including tuberculosis (TB); neoplastic, purulent, or radiation etiologies
- Post-thoracic blunt trauma (e.g., motor vehicle accident)
- Myocarditis
- Systemic autoimmune diseases with exception of Still’s disease, pregnancy, hx HIV, prednisone > 60 mg/day, positive Hep B or C, serious infection

**Condition:** Pericarditis

**PI:** David Lin, MD

**Research Contact:**
Christine Majeski
Christine.Majeski@allina.com | 612-863-3546

**Sponsor:** Kiniksa Pharmaceuticals

**Status:** In Follow-Up

MHIF was first in the world to enroll in this trial and has 4 subjects enrolled out of the 9 in the world. Pericarditis patients are experiencing significant benefits and most often have no chest pain after starting this medication.
MHIF Featured Study: Vesalius

**DESCRIPTION:**
The purpose of this trial is to evaluate the effect Evolocumab has in reducing the risk of coronary heart disease (CHD) death, MI, stroke, and ischemia-driven arterial revascularization in adults at high risk of cardiovascular events without prior MI or stroke.

**CRITERIA LIST/QUALIFICATIONS:**

**Inclusion**
- ≥ 50 years (men); or ≥ 55 years (women) to < 80 years of age (either sex)
- LDL-C ≥ 100 mg/dL (≥ 2.6 mmol/L) or HDL-C ≥ 130 mg/dL (≥ 3.4 mmol/L) on maximal tolerated therapy
- CAD w revasc
- High calcium score (≥100)
- TIA, carotid revasc, PVD
- DM with microvascular disease
- **PLUS** one high risk criteria: polyvascular disease, metabolic syndrome, Lp(a)>125, LDL ≥130, known FH, fam hx premature CAD, CRP ≥3, current tobacco, ≥ 65 yrs, eGFR < 45

**CONDITION:**
High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

**PI:**
Thomas Knickelbine, MD

**RESEARCH CONTACT:**
Ezi Ebere
Ezi.Ebere@allina.com | 612-863-4393

**SPONSOR:**
Amgen Inc.

OPEN AND ENROLLING:
Please Refer Patients!
MHIF FEATURED STUDY: VISITAG SURPOINT

DESCRIPTION:
Primary objective of study is to demonstrate safety and 12-month effectiveness of Tag Index-guided ablation using VISITAG SURPOINT™ Module with External Processing Unit when used with THERMOCOOL SMARTTOUCH® SF (STSF) and THERMOCOOL SMARTTOUCH® (ST) catheters for pulmonary vein isolation (PVI) in the treatment of subjects with drug refractory symptomatic paroxysmal AF.

CRITERIA LIST/QUALIFICATIONS:

Inclusion
1. Symptomatic paroxysmal AF; had at least 1 AF episode electrocardiographically documented within 1 year prior to enrollment
   Documentation may include ECG, TTM, Holter monitor or telemetry strip
2. Failed at least 1 antiarrhythmic drug (AAD Class I or III) as evidenced by recurrent symptomatic AF, or intolerable to the AAD

Exclusion
1. Previous surgical or catheter ablation for AF
2. Previous cardiac surgery (including CABG) within past 6 months (180 days)
3. Valvular cardiac surgical/percutaneous procedure (i.e., ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve)

AF is the most common sustained arrhythmia. It affects 0.4% to 1% of the general population, and increases in prevalence with age.
**MHIF FEATURED STUDY:**
**WARRIOR - Women's Ischemia Trial**

**DESCRIPTION:**
The purpose of WARRIOR (Women's Ischemia Trial to Reduce Events in Non-Obstructive CAD) is to evaluate if intensive medical therapy (IMT) (potent statin plus ACE-I or ARB) is better than usual care in women who have s/s of suspected ischemia but no obstructive CAD (defined as <50 stenosis). The hypothesis is that IMT will reduce MACE 20% vs. usual care.

**CRITERIA LIST/ QUALIFICATIONS:**

<table>
<thead>
<tr>
<th><strong>Inclusion</strong></th>
<th><strong>Exclusion</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Signs and symptoms of suspected ischemia prompting referral for further evaluation by coronary angiography or coronary CT angiogram within previous 3 years</td>
<td>• Hx NIHCM</td>
</tr>
<tr>
<td>• Non-obstructive CAD defined as 0-50% diameter reduction of a major epicardial vessel</td>
<td>• ACS within 30 days</td>
</tr>
<tr>
<td></td>
<td>• LVEF&lt; 40% NYHA HF class III-IV</td>
</tr>
<tr>
<td></td>
<td>• Prior intolerance to ACE/ARB</td>
</tr>
<tr>
<td></td>
<td>• ESRD on dialysis</td>
</tr>
<tr>
<td></td>
<td>• Severe valvular disease requiring TVAR within 3 years</td>
</tr>
<tr>
<td></td>
<td>• Stroke within 180 days</td>
</tr>
</tbody>
</table>

**CONDITION:**
Non-Obstructive CAD in Women

**PI:**
Retu Saxena, MD

**RESEARCH CONTACT:**
Steph Ebnet
Stephanie.ebnet@allina.com | 612-863-6286

**SPONSOR:**
University of FL Funded by the Department of Defense

**OPEN AND ENROLLING:**
EPIC message: Research MHIF Patient Referral
CALLING FOR RESEARCH REFERRALS!

Talk with your patients about their options, including clinical research.

Bookmark this link as a resource to access current, featured studies and MHIF research contact information:

mplsheart.org/studies
## MHIF Research Team Contacts

### Valve / Structural Heart

<table>
<thead>
<tr>
<th>Name</th>
<th>Email Address</th>
<th>Phone Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aisha Ahmed</td>
<td><a href="mailto:Aisha.Ahmed@allina.com">Aisha.Ahmed@allina.com</a></td>
<td>612-863-3974</td>
</tr>
<tr>
<td>Kate Jappe</td>
<td><a href="mailto:Kate.Jappe@allina.com">Kate.Jappe@allina.com</a></td>
<td>612-863-7347</td>
</tr>
<tr>
<td>Karen Meyer</td>
<td><a href="mailto:Karen.Meyer2@allina.com">Karen.Meyer2@allina.com</a></td>
<td>612-863-5855</td>
</tr>
<tr>
<td>Jennifer Nguyen</td>
<td><a href="mailto:Jennifer.Nguyen@allina.com">Jennifer.Nguyen@allina.com</a></td>
<td>612-863-9291</td>
</tr>
<tr>
<td>Sara Olson</td>
<td><a href="mailto:Sara.Olson@allina.com">Sara.Olson@allina.com</a></td>
<td>612-863-7601</td>
</tr>
<tr>
<td>Alyssa Taffe</td>
<td><a href="mailto:Alyssa.Taffe@allina.com">Alyssa.Taffe@allina.com</a></td>
<td>612-863-7821</td>
</tr>
<tr>
<td>Lisa Tindell</td>
<td><a href="mailto:Lisa.Tindell@allina.com">Lisa.Tindell@allina.com</a></td>
<td>612-863-3816</td>
</tr>
</tbody>
</table>
# MHIF Research Team Contacts

**Interventional / Endovascular / Imaging / CCAD Science Center**

<table>
<thead>
<tr>
<th>Name</th>
<th>Email Address</th>
<th>Phone Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Teri Dalager</td>
<td><a href="mailto:Teresa.Dalager@allina.com">Teresa.Dalager@allina.com</a></td>
<td>612-863-0243</td>
</tr>
<tr>
<td>JoAnne Goldman</td>
<td><a href="mailto:JoAnne.Goldman@allina.com">JoAnne.Goldman@allina.com</a></td>
<td>612-863-3793</td>
</tr>
<tr>
<td>Amy McMeans</td>
<td><a href="mailto:Amy.McMeans@allina.com">Amy.McMeans@allina.com</a></td>
<td>612-863-3895</td>
</tr>
<tr>
<td>Pamela Morley</td>
<td><a href="mailto:Pamela.Morley@allina.com">Pamela.Morley@allina.com</a></td>
<td>612-863-6066</td>
</tr>
<tr>
<td>Rose Peterson</td>
<td><a href="mailto:Rose.Peterson@allina.com">Rose.Peterson@allina.com</a></td>
<td>612-863-6051</td>
</tr>
<tr>
<td>Bavana Rangan</td>
<td><a href="mailto:Bavana.Rangan@allina.com">Bavana.Rangan@allina.com</a></td>
<td>612-863-3852</td>
</tr>
<tr>
<td>Kalia Yang</td>
<td><a href="mailto:Kalia.Yang@allina.com">Kalia.Yang@allina.com</a></td>
<td>612-863-5507</td>
</tr>
<tr>
<td>Name</td>
<td>Email Address</td>
<td>Phone Number</td>
</tr>
<tr>
<td>-----------------</td>
<td>--------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Carina Benson</td>
<td><a href="mailto:Carina.Benson@allina.com">Carina.Benson@allina.com</a></td>
<td>612-863-6288</td>
</tr>
<tr>
<td>Jane Fox</td>
<td><a href="mailto:Jane.Fox@allina.com">Jane.Fox@allina.com</a></td>
<td>612-863-6289</td>
</tr>
<tr>
<td>Jacob Jensen</td>
<td><a href="mailto:Jacob.Jensen@allina.com">Jacob.Jensen@allina.com</a></td>
<td>612-863-8818</td>
</tr>
<tr>
<td>Sarah Schwager</td>
<td><a href="mailto:Sarah.Schwager@allina.com">Sarah.Schwager@allina.com</a></td>
<td>612-863-6257</td>
</tr>
<tr>
<td>Kari Thomas</td>
<td><a href="mailto:Kari.M.Thomas@allina.com">Kari.M.Thomas@allina.com</a></td>
<td>612-863-7493</td>
</tr>
<tr>
<td>Kari Williams</td>
<td><a href="mailto:Kari.Williams@allina.com">Kari.Williams@allina.com</a></td>
<td>612-863-0027</td>
</tr>
</tbody>
</table>
# MHIF Research Team Contacts

## EP / Prevention

<table>
<thead>
<tr>
<th>Name</th>
<th>Email Address</th>
<th>Phone Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jacob Cohen</td>
<td><a href="mailto:Jacob.Cohen@allina.com">Jacob.Cohen@allina.com</a></td>
<td>612-863-3983</td>
</tr>
<tr>
<td>Ezi Ebere</td>
<td><a href="mailto:Ezinwanyi.Ubani-Ebere@allina.com">Ezinwanyi.Ubani-Ebere@allina.com</a></td>
<td>612-863-4393</td>
</tr>
<tr>
<td>Stephanie Ebnet</td>
<td><a href="mailto:Stephanie.Ebnet@allina.com">Stephanie.Ebnet@allina.com</a></td>
<td>612-863-6286</td>
</tr>
<tr>
<td>Christine Majeski</td>
<td><a href="mailto:Christine.Majeski@allina.com">Christine.Majeski@allina.com</a></td>
<td>612-863-3546</td>
</tr>
<tr>
<td>Andrew Nauertz</td>
<td><a href="mailto:Andrew.Nauertz@allina.com">Andrew.Nauertz@allina.com</a></td>
<td>612-863-1661</td>
</tr>
<tr>
<td>Andrea Sarafolean</td>
<td><a href="mailto:Andrea.Sarafolean@allina.com">Andrea.Sarafolean@allina.com</a></td>
<td>612-863-3941</td>
</tr>
<tr>
<td>Robin Zawacki</td>
<td><a href="mailto:Robin.Zawacki@allina.com">Robin.Zawacki@allina.com</a></td>
<td>612-863-1674</td>
</tr>
</tbody>
</table>